Open Access Medical Books



Edited by Dieter Schoepf .

320 pages .
Open Access .

Since the turn of the century, our understanding of affective serious mental illness has increased apace. With its onset during early childhood or the crucial period of adolescence, affective disorders often have a significant impact on the (normal) life trajectory, not to mention the effect of those families who have been touched by mental illness. Individuals suffering from affective disorders, such as early-onset major depression, bipolar disorder and schizoaffective disorder, which fall into this rubric, not only have a profile of severe and long-lasting morbidity compared to the general population, they frequently continue to receive less than adequate care - despite the many millions of dollars spent each year on the mentally ill. In addition to recognizing the precise source and environmental commonalities, the combination of biologically orientated investigations into genetic and epigenetic factors, neurochemical and molecular-biological changes in the brain, structural brain and functional neural networking abnormalities, and therapeutic studies have consolidated the current view of a cumulative risk model for the onset and the maintenance of affective disorders.
With respect to causal treatability, affective disorders are characterized by a reduced responsiveness to classical pharmacological and short-term behavioral interventions.
The impact of these diseases is - more often than not - pervasive; in up to 30% they develop from an episodic into a chronic or pharmacologic treatment resistant course. Specifically, depression and cognitive impairment usually have a major detrimental effect on personal, social and occupational functioning with marked impairment of dyadic reciprocity, and are associated with considerable personal and healthcare utilisation burden. Therefore the awareness of an urgent need for evidence-based “personalized” approach for chronic and treatment resistant courses is slowly growing in the field of psychiatry. Such approach targets available pharmaceuticals and psychotherapeutic interventions to specific diagnostic subgroups, determines the interplay between psychotherapy and neurobiology, and implements stepped care models of combined treatment models. It can be assumed, that the challenge of an evidence-based “personalized” approach will entail pharmacological progress in the future. Additional advance can be expected from new clinical curiosity combined with pharmacodynamic hypothesis testing. Finally, by the research of the underlying neural mechanisms and the impact of pharmacotherapy and psychotherapy on behavioural and neural network functioning, more is learned about the fundamental processes of learning and memory. The clinical utility of an evidence-based “personalized” approach remains, however, to be evaluated in distinct patient groups....

Dr. Dieter Schoepf
CBASP Centre of Competence, University of Bonn,



Section 1 Neurobiological Frontiers .

 1 Neurobiological Background of Affective Disorders 3 Peter Falkai, Berend Malchow and Andrea Schmitt

 2 HPA Axis Modulation in the Treatment of Mood Disorders 21 Lauren B. Ozbolt and Charles B. Nemeroff

 3 The Pharmacological Frontiers in Treatment Resistant Major Depression 41 Tom K. Birkenhäger and Henricus G. Ruhé

Section 2 Translational Search for Targets to Improve Treatment of Psychiatric Disorders .

 4 Altered Associative Learning and Learned Helplessness in Major Depression 57 Carsten Diener

 5 Emotional and Motivational Processes in Bipolar Disorder: A Neural Network Perspective 79 Michèle Wessa and Julia Linke

 6 CBT in Affective Disorders – New Frontiers 121 Larissa Wolkenstein and Martin Hautzinger

Section 3 Novel Psychotherapeutic Developments .

 7 CBASP with Intensified Significant Other History Exercise for Chronic Major Depression with Antecedent Dysthymic Disorder in Outpatient Treatment: Rationale, Assessment and Effects on the Hypothesized Core Content of the Patient’s in-Session Interpersonal Fear in Relation to Symptom Reduction 153 Dieter Schoepf

 8 Adaptation of Cognitive Behavioral Analysis System of Psychotherapy in a 29 Year Old Female Patient with Chronic Major Depression and Antecedent Dysthymic Disorder Who Switched Under Combined SSRI/CBASP Outpatient Treatment into Bipolarity: A Case Report 183 Viola Oertel-Knöchel and Dieter Schoepf

 9 Group Cognitive Behavioral Analysis System of Psychotherapy (Group-CBASP): Adaptation to a Group Modality for the Treatment of Chronic Depression 203 Liliane Sayegh and Gustavo Turecki

Section 4 Co-Morbidity Frontiers .

 10 Co-Occurring Chronic Depression and Alcohol Dependence: A Novel Treatment Approach 237
J. Kim Penberthy, Christopher J. Gioia, Andrea Konig, Aaron M. Martin and Stephanie A. Cockrell

 11 Psychosocial Intervention for Co-Existing MDD and PTSD 257 Todd K. Favorite and Todd Vance

 12 Group Intervention for Chronic Depression and PTSD 269 Todd K. Favorite and Kayla J. Conrad

 13 Depression, Vascular Conditions and Chronicity 279 Adrie Seldenrijk, Nicole Vogelzangs, Patricia van Oppen, Brenda Penninx and Anneke van Schaik

Section 5 Challenging the Stigma of Serious Mental Illness .

 14 A Journey Through Schizophrenia 297 Susan L. Renes

You've just read an article category Neuroscience and Behavioural Disorders and Diseases of the Nervous System by title TEXTBOOK : PSYCHIATRIC DISORDERS – NEW FRONTIERS IN AFFECTIVE DISORDERS. You can bookmark this page URL Thank you!
Published by: Unknown - Friday, May 24, 2013


  1. Thanks, its a very good information of sharing and making people know about the activities that are being carried out.I think I can find more useful information here, thanks.